What is the exact half-life of Trenbolone Acetate in Genesis Trenbol 100?

The plasma half-life of Trenbolone Acetate following intramuscular injection is approximately 48–72 hours, as established in radioimmunoassay-based elimination studies on esterified trenbolone compounds. This means active circulating levels drop to roughly half their peak value within two to three days, making it one of the shortest-acting trenbolone esters available and the primary reason frequent dosing is required.

How many days does it take for Trenbol 100 to reach a stable steady-state concentration?

Using the four-to-five half-life rule standard in clinical pharmacokinetics, Trenbol 100 reaches functional steady-state circulating concentrations within approximately 8–10 days of consistent every-48-hour dosing. This contrasts sharply with long-ester trenbolone variants, where plateau is not achieved for three to four weeks, giving Trenbol 100 a significant early-cycle pharmacokinetic advantage for monitoring response.

How does Trenbolone Acetate's release profile compare to Trenbolone Enanthate pharmacokinetically?

Trenbolone Acetate carries a half-life of 48–72 hours versus approximately 7–10 days for Trenbolone Enanthate. This means the acetate ester reaches and exits steady-state concentration far faster, enabling quicker therapeutic onset and more rapid clearance after the final injection. For athletes prioritising pharmacokinetic agility — particularly those managing cycle length around competition dates — the acetate ester's release profile is markedly more responsive.

How should Trenbol 100 be drawn and measured using an insulin syringe for accurate dosing from the 10 ml vial?

A standard 1 ml insulin syringe (100-unit scale) maps directly to 1 ml of solution when drawing Trenbol 100 at 100 mg/ml, so 100 units on the syringe equals a 100 mg dose. Wipe the vial stopper with an alcohol swab before each draw, inject air equal to the intended draw volume to equalise pressure, then aspirate slowly to avoid air bubbles that would reduce measured dose accuracy.

What are the correct storage conditions for a Genesis Trenbol 100 10 ml vial after first opening?

After the septum has been first punctured, Trenbol 100 should be stored at 15–25 °C away from direct light and moisture; refrigeration is not required but is acceptable. The multi-dose vial contains a benzyl benzoate/benzyl alcohol carrier system that maintains antimicrobial integrity across multiple draws when proper aseptic technique is used. Discard any vial showing precipitate, discolouration, or particulate matter regardless of remaining volume. (2) angle_used

Top Seller

Genesis

Trenbol 100 100mg/ml 10ml Vial by Genesis

Name: Trenbol 100 100mg/ml 10ml Vial by Genesis
Brand: Genesis
SKU: INJ-TACE-GES-100-007
Price: 48.00 EUR
Availability: InStock

Genesis Trenbol 100 is a short-ester oil-based injectable delivering Trenbolone Acetate at 100 mg per millilitre in a 10 ml multi-dose vial, engineered around the acetate ester's characteristically brief circulatory half-life of approximately 48–72 hours for rapid pharmacokinetic turnover. Because its active window closes faster than longer-ester trenbolone variants, Trenbol 100 gives athletes granular, session-by-session control over circulating hormone levels — a property that makes mid-cycle adjustment straightforward. Quality is verified through HPLC potency assay at finished-product stage, with every released batch carrying documented certificates of analysis.

€48.00Free shipping on orders over €300

In stock

Ships within 48 h Lab-tested batch

Rapid pharmacokinetic onset: circulating trenbolone levels are detectable within hours of the first injection due to the acetate ester's short chain length.
Precise mid-cycle adjustability — dose or frequency changes reflect in serum levels within days, not weeks.
Fast post-cycle clearance enables PCT to commence sooner than with enanthate or hexahydrobenzylcarbonate variants.
100 mg/ml concentration at 10 ml volume provides 30+ injection sessions at common dosing volumes without reformulation.
HPLC-verified concentration accuracy ensures the pharmacokinetic calculations a user applies in practice match the actual milligrams injected.
Manufactured under GMP-compliant fill-finish conditions with LAL endotoxin screening for safety confidence across every vial.
Genesis batch-release documentation travels with the product, supporting traceability for athletes who require chain-of-custody records.

Phase	Dosage	Note
Introductory (Weeks 1–4)	100 mg every 72 hours (approx. 233 mg/week)	Three-day spacing allows observation of individual pharmacokinetic response before shortening interval; steady-state reached by day 10–12.
Intermediate (Weeks 1–8)	100 mg every 48 hours (approx. 350 mg/week)	Standard every-other-day protocol aligned to the 48–72 h half-life; maintains tighter peak-to-trough ratio than 72 h spacing.
Advanced / Short Blast (Weeks 1–6)	150 mg every 48 hours (approx. 525 mg/week)	Higher-volume users; shorter cycle duration leverages fast clearance for rapid post-blast recovery window.
Maintenance / Cruise (Ongoing)	50–75 mg every 48 hours	Sub-maximal androgenic load; acetate ester pharmacokinetics permit dose reduction to reflect within 4–6 days.

Key takeaways

Expect a 48–72-hour half-life for rapid pharmacokinetic turnover.
Inject every two days to maintain steady androgen signalling.
Reach functional steady-state within 8–10 days of consistent dosing.
Verify each batch's concentration via HPLC before committing to a protocol.
Anticipate faster post-cycle clearance compared to long-ester trenbolone variants.

Pharmacokinetic Profile of Trenbolone Acetate: Half-Life, Release Rate, and Circulating Behaviour

Genesis Trenbol 100 is characterised pharmacokinetically by the short active duration conferred by the acetate ester, which results in a plasma half-life measured in the range of 48–72 hours under standard intramuscular administration conditions — a figure derived from established radioimmunoassay elimination studies on esterified trenbolone compounds. This abbreviated half-life distinguishes Trenbolone Acetate decisively from Trenbolone Enanthate (half-life approximately 7–10 days) and Trenbolone Hexahydrobenzylcarbonate (approximately 14 days), meaning serum concentrations in Trenbol 100 users decline to sub-therapeutic levels within three to four days of a missed dose. That responsiveness is a deliberate pharmacokinetic feature: athletes who require tight hormonal management appreciate that circulating trenbolone concentrations drop predictably and promptly when administration is halted.

Injection Frequency and Steady-State Kinetics

To maintain stable androgenic signalling throughout a cycle, Trenbol 100 requires injection every 48–72 hours — a dosing interval calibrated to the half-life rather than to convenience. Using the standard pharmacokinetic steady-state formula (approximately four to five half-lives to reach plateau), a user injecting 100 mg every two days reaches functional steady-state circulating levels within roughly 8–10 days. Compared to long-ester variants, where steady-state is not achieved for three to four weeks, the Trenbol 100 release profile allows meaningful serum-level feedback within the first training block of a cycle. Genesis supplies this compound at 100 mg/ml concentration, so a 1 ml draw per injection session delivers a precise, measurable unit dose without requiring volume arithmetic.

Quality Infrastructure Supporting Pharmacokinetic Consistency

Pharmacokinetic predictability is only clinically meaningful when the stated concentration matches the actual milligram-per-millilitre content of the vial. Genesis addresses this by submitting every Trenbol 100 batch to HPLC potency verification at finished-product stage — an analytical method capable of resolving concentration deviations at the sub-percentage level. LAL endotoxin screening provides the microbial safety checkpoint, and GMP-compliant fill-finish operations govern the sterile manufacturing environment throughout. Trenbol 100 therefore delivers not only a pharmacokinetically favourable ester choice but also the analytical consistency necessary for users to rely on dose-response relationships from injection to injection.

Usage

Confirm vial integrity before drawing: inspect the 10 ml vial for particulate matter, discolouration, or stopper damage — pharmacokinetic consistency begins with an uncontaminated draw.
Calculate your injection interval based on the 48–72 hour half-life: mark injection days on a calendar before the cycle begins to avoid accidental gaps that break steady-state.
Swab the rubber septum with 70 % isopropyl alcohol and allow 30 seconds of drying time; introduce air equal to your intended draw volume before aspirating Trenbol 100 to ease withdrawal from the 10 ml vial.
Draw your measured volume — typically 0.5–1.5 ml depending on your pharmacokinetically calculated weekly target — and expel any trapped air bubble before capping the needle.
Rotate injection sites systematically (glutes, quads, delts in rotation) across every-other-day injections to prevent tissue accumulation at any single depot site, which would distort local absorption kinetics.
Log each injection time precisely: because Trenbol 100's half-life is short, consistent injection timing within a ±4-hour window of your scheduled interval is important for maintaining predictable serum-level patterns throughout the cycle.

Warnings

Contraindications: Trenbol 100 is contraindicated in individuals with diagnosed prostate or breast carcinoma, severe hepatic impairment, active cardiovascular disease, or hypersensitivity to any component of the formulation including benzyl alcohol. Individuals under 21 years of age should not use this compound due to ongoing endocrine axis maturation. Women of childbearing potential must avoid Trenbolone Acetate given its androgenic virilisation risk.

Side_Effects: Androgenic effects including accelerated androgenic alopecia, acne vulgaris, and seborrhoea are dose-dependent. Trenbolone Acetate's strong progestogenic activity can suppress endogenous gonadotrophin secretion rapidly — a consequence compounded by its short half-life cycling frequently through the HPG axis. Cardiovascular risk includes adverse lipid remodelling (LDL elevation, HDL suppression), left ventricular hypertrophy with sustained use, and haematocrit elevation. Trenbolone-specific adverse events include night sweats, reduced aerobic endurance, and elevated resting heart rate — monitor and reduce dose if resting heart rate consistently exceeds 90 bpm.

Monitoring: Serum lipid panel (LDL, HDL, total cholesterol) at baseline and every four weeks of active use. Haematocrit and haemoglobin checked monthly; haematocrit above 52 % warrants dose interruption. Liver enzyme panels (AST, ALT) and renal function markers are recommended at cycle mid-point. Blood pressure should be self-monitored at least twice weekly; persistent systolic readings above 140 mmHg require immediate dose reassessment.

PCT: Because Trenbolone Acetate's half-life is approximately 48–72 hours, suppression of the hypothalamic-pituitary-gonadal axis clears pharmacokinetically faster than with long-ester trenbolone compounds. Post-cycle therapy with a SERM (Clomiphene citrate 50 mg/day or Tamoxifen 20 mg/day) should commence no later than five days after the final injection. A standard 4-week PCT protocol is recommended; hCG pre-loading during the final week of the cycle may support a more robust gonadotrophin recovery response.

Frequently asked questions

What is the exact half-life of Trenbolone Acetate in Genesis Trenbol 100?: The plasma half-life of Trenbolone Acetate following intramuscular injection is approximately 48–72 hours, as established in radioimmunoassay-based elimination studies on esterified trenbolone compounds. This means active circulating levels drop to roughly half their peak value within two to three days, making it one of the shortest-acting trenbolone esters available and the primary reason frequent dosing is required.
How many days does it take for Trenbol 100 to reach a stable steady-state concentration?: Using the four-to-five half-life rule standard in clinical pharmacokinetics, Trenbol 100 reaches functional steady-state circulating concentrations within approximately 8–10 days of consistent every-48-hour dosing. This contrasts sharply with long-ester trenbolone variants, where plateau is not achieved for three to four weeks, giving Trenbol 100 a significant early-cycle pharmacokinetic advantage for monitoring response.
How does Trenbolone Acetate's release profile compare to Trenbolone Enanthate pharmacokinetically?: Trenbolone Acetate carries a half-life of 48–72 hours versus approximately 7–10 days for Trenbolone Enanthate. This means the acetate ester reaches and exits steady-state concentration far faster, enabling quicker therapeutic onset and more rapid clearance after the final injection. For athletes prioritising pharmacokinetic agility — particularly those managing cycle length around competition dates — the acetate ester's release profile is markedly more responsive.
How should Trenbol 100 be drawn and measured using an insulin syringe for accurate dosing from the 10 ml vial?: A standard 1 ml insulin syringe (100-unit scale) maps directly to 1 ml of solution when drawing Trenbol 100 at 100 mg/ml, so 100 units on the syringe equals a 100 mg dose. Wipe the vial stopper with an alcohol swab before each draw, inject air equal to the intended draw volume to equalise pressure, then aspirate slowly to avoid air bubbles that would reduce measured dose accuracy.
What are the correct storage conditions for a Genesis Trenbol 100 10 ml vial after first opening?: After the septum has been first punctured, Trenbol 100 should be stored at 15–25 °C away from direct light and moisture; refrigeration is not required but is acceptable. The multi-dose vial contains a benzyl benzoate/benzyl alcohol carrier system that maintains antimicrobial integrity across multiple draws when proper aseptic technique is used. Discard any vial showing precipitate, discolouration, or particulate matter regardless of remaining volume. (2) angle_used

Manufacturer

Genesis has cultivated its reputation in the injectable anabolic segment through an approach to customer support that is uncommon among contract-fill manufacturers: structured, accessible post-purchase service backed by documentation that travels with the product. Where many producers treat the point of sale as the endpoint of their obligation, Genesis extends its accountability through batch-specific certificates of analysis that end-users can reference when questions arise about concentration, sterility, or shelf-life — a practical support mechanism that removes the ambiguity typically associated with post-market product queries. The customer service architecture at Genesis is built around the premise that a user running a pharmacokinetically demanding compound like Trenbolone Acetate — where dosing precision matters acutely — should have access to verifiable, batch-level information rather than generic formulation claims. Technical enquiries directed to the Genesis service channel are handled with reference to the actual released-batch documentation, enabling specific answers about HPLC potency results or LAL endotoxin screening outcomes rather than deflection to category-level assurances. This orientation toward documented, traceable customer support is reinforced by Genesis's distribution model, which ensures that certificates of analysis and batch traceability records are matched to the correct vial sets at the point of despatch.

Product details

Brand	Genesis
Active ingredient	trenbolone acetate
Also known as	Tren A, Trenbolone Acetate, Finaplix, Trenbol 100, Genesis Tren A
Strength	100 mg
Form	Vial
Pack size	1 piece
Item number	INJ-TACE-GES-100-007

Reviews

No reviews yet. Be the first to review this product.

Write a review

Reviews are written by users of this shop and are checked editorially before publication. Unless labelled “Verified purchase”, we do not verify that the review is based on an actual purchase.

Similar products

Optimal Dosage

Acro-Trenbolone 100mg/ml 10ml Vial by Beligas Pharmaceuticals

Acro-Trenbolone is a sterile, oil-based intramuscular solution delivering Trenbolone Acetate at 100 mg per millilitre across a 10 ml multi-dose vial — engineered specifically to bypass hepatic first-pass catabolism and achieve near-complete systemic bioavailability that no oral anabolic compound can match. Because the active hormone enters circulation directly through intramuscular absorption rather than the gastrointestinal tract, essentially none of the injected dose is destroyed before it reaches target androgen receptors. Quality assurance at Beligas Pharmaceuticals is enforced through a layered release protocol: HPLC-verified potency, LAL endotoxin testing, and GMP-certified production conditions — each checkpoint documented before the vial leaves the facility.

€48.00

Trenbolin-100 100mg/ml 10x1ml Ampoules by BM Pharmaceuticals

Fast Acting

Trenbolin-100 100mg/ml 10x1ml Ampullen by BM Pharmaceuticals

Trenbolin-100 is an oil-based injectable Trenbolone Acetate formulated at 100mg/ml, engineered for rapid onset of action — making it the go-to ester choice when time-to-effect and dosing efficiency both matter. Each 1ml ampoule delivers a precise, single-use dose of one of the most potent anabolic compounds available, with the acetate ester's short chain enabling plasma concentration peaks within 24–48 hours of administration. Potency is confirmed batch-to-batch via HPLC quantification; sterility is validated through LAL endotoxin screening — both conducted under GMP-certified clean-room conditions at BM Pharmaceuticals' Indian facility.

€54.00

High Concentration

TrenaTrex 150mg/ml 10ml Vial by Concentrex Labs

TrenaTrex by Concentrex Labs delivers Trenbolone Acetate at 150 mg/ml in a 10 ml multi-dose vial, engineered for athletes who demand structured, time-anchored injection scheduling to sustain stable circulating hormone levels across every training week. The acetate ester's approximately 48-hour half-life means that consistent administration timing — not rough approximation — is the primary determinant of anabolic continuity throughout a cycle. Every batch undergoes HPLC potency quantification and LAL endotoxin testing before release, confirming both the 150 mg/ml concentration and pyrogen-free sterility.

€55.00

Brand Quality

Trenbolone 100 100mg/ml 10ml Vial by Dragon-Pharma

Dragon-Pharma Trenbolone 100 is a single-ingredient injectable solution delivering Trenbolone Acetate at 100mg/ml across a 10ml multi-dose vial, specifically suited to frontloading strategies where a calculated loading dose accelerates the attainment of target blood levels from the very first injection day. Because the acetate ester carries one of the shortest half-lives among trenbolone esters (approximately 2–3 days), the gap between first injection and productive working concentration is inherently short — and a deliberate frontload compresses it further, letting athletes enter the active phase of a cycle days earlier than a flat-dose approach permits. Every batch of Trenbolone 100 passes HPLC potency verification and LAL endotoxin screening before release; lot-specific certificates confirm that declared concentration and sterility specifications are met across the full 10ml fill.

€46.00

Stack it with

Pairs well with these products.

High Concentration

Quant-Equipoise 300mg/ml 10ml Vial by Beligas Pharmaceuticals

Quant-Equipoise by Beligas Pharmaceuticals is a high-concentration injectable anabolic agent delivering 300 mg of Boldenone Undecylenate per millilitre in a 10 ml multi-dose vial, purpose-built for integration into contemporary cycle structures where weekly injection frequency and volume efficiency are primary design criteria. The compound's extended ester profile supports low-frequency administration windows that align with modern 7-day dosing blocks used in both bulking and body-recomposition protocols. Quality assurance is enforced at two independent checkpoints: HPLC-verified potency assay and LAL bacterial endotoxin testing — both completed before batch release under Beligas's GMP-certified production framework.

€47.00

Bolden-250 250mg/ml 10x1ml Ampoules by BM Pharmaceuticals

Long-Acting Formula

Bolden-250 250mg/ml 10x1ml Ampullen by BM Pharmaceuticals

Bolden-250 is a veterinary-derived anabolic compound reformulated for human performance use, delivering Boldenone Undecylenate at 250 mg/ml via single-dose ampoule — distinguished by its exceptionally prolonged plasma half-life of approximately 14 days, which governs the entire pharmacokinetic profile and dictates injection scheduling. The undecylenate ester attached to the boldenone base controls the rate of hydrolysis in muscle tissue, producing a slow, steady release curve that maintains stable serum concentrations over extended periods. Quality verification is built into every step of production: HPLC-confirmed potency, LAL endotoxin screening, and GMP-compliant fill-finish at BM Pharmaceuticals' certified facility.

€48.00

Brand Quality

EquiTrex 350mg/ml 10ml Vial by Concentrex Labs

EquiTrex is a high-concentration boldenone undecylenate injectable — 350 mg per millilitre in a 10 ml vial — engineered to serve distinct roles across both the blast and cruise phases of a structured performance cycle. Its extended ester release supports stable androgen exposure during lower-dose cruise periods while delivering meaningful anabolic output when dose is escalated during a blast. Quality assurance at Concentrex Labs is built on HPLC potency verification and LAL endotoxin screening; every released batch carries documented evidence of sterility and concentration accuracy.

€52.00

Pro Choice

EQ 300 300mg/ml 10ml Vial by Dragon-Pharma

Dragon-Pharma EQ 300 delivers Boldenone Undecylenate at 300 mg/ml in a 10 ml multi-dose vial, formulated specifically for older athletes and TRT-adjacent users who require a mild yet effective anabolic agent to complement age-related hormonal management strategies. Its gradual plasma release profile makes it particularly suited to the steadier hormonal environment that men over 40 typically need to maintain lean mass, bone density support, and nitrogen retention without the volatility of shorter-ester androgens. Quality is assured at the batch level: every vial passes HPLC content verification and LAL endotoxin screening before release under full GMP compliance.

€44.00